Aquestive Therapeutics, Inc.(AQST)

Description: Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.

---

Keywords: Pharmaceutical Disease Drugs Psychoactive Drugs Opioids Epilepsy Chloroarenes Gabaa Receptor Positive Allosteric Modulators Amyotrophic Lateral Sclerosis Lactams Seizure Neuroendocrine Tumors Xone Benzodiazepines Buprenorphine/Naloxone Neuroendocrine Tumor Parkinson’s Disease Anaphylaxis Riluzole

---

Home Page: www.aquestive.com

AQST Technical Analysis

30 Technology Drive
Warren, NJ 07059
United States
Phone: 908 941 1900

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)